Table 2.
Models | N | Incident HF Hazard Ratios |
95% Confidence Intervals |
---|---|---|---|
Unadjusted | 12,363 | 3.02 | (2.59-3.52) |
Overall adjusted* | 11,743 | 1.54 | (1.30-1.82) |
Age-stratified analysis † | |||
Age ≤55 years | 6,868 | 1.90 | (1.41-2.55) |
Age >55 years | 4,875 | 1.37 | (1.12-1.69) |
Race and gender stratified analysis † | |||
White Women | 4,528 | 1.59 | (1.13-2.23) |
African-American Women | 1,885 | 1.60 | (1.14-2.24) |
White Men | 4,155 | 1.31 | (1.00-1.72) |
African-American Men | 1,175 | 1.71 | (0.98-2.99) |
Secondary Analyses with Exclusions | |||
Exclusion of diabetes at baseline† | 10,507 | 1.50 | (1.22-1.84) |
Exclusion of hypertension at baseline† | 7,936 | 1.34 | (1.00-1.80) |
Exclusion of individuals on anti- hypertensives (ACE inhibitors, beta- blockers or diuretics) at baseline† |
9,111 | 1.47 | (1.17-1.85) |
Exclusion of CHD at baseline† | 11,329 | 1.52 | (1.27-1.82) |
Exclusion of psychiatric or Parkinson’s medications at baseline† |
11,017 | 1.43 | (1.19-1.72) |
Exclusion of HF cases from first 2 years of follow-up† |
11,568 | 1.60 | (1.35, 1.90) |
Models adjusted for baseline variables: age, gender, race by center, body mass index, educational level, smoking, alcohol use, diabetes mellitus, mean supine systolic blood pressure, resting heart rate, left ventricular hypertrophy, coronary heart disease, and hypertension
For secondary analyses, all of the above covariates were adjusted for except the stratified covariates